WHAT IS CLAIMED IS:

1. A swellable core dosage form comprising a dispersion of amorphous 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d_3)pyridazine-3-carboxamide (BMS-986165) dispersed in a polymer matrix.

2. The swellable core dosage form according to claim 1, wherein the polymer matrix comprises hydroxypropyl methylcellulose acetate succinate (HPMCAS).

3. The swellable core dosage form according to claim 1, wherein the dispersion of amorphous 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d_3)pyridazine-3-carboxamide (BMS-986165) dispersed in a polymer matrix comprises: 15% amorphous BMS-986165 : 85% hydroxypropyl methylcellulose acetate succinate (HPMCAS).

4. The swellable core dosage form according to any one of claims 1-3, wherein the dispersion of amorphous 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d_3)pyridazine-3-carboxamide (BMS-986165) dispersed in a polymer matrix is a spray-dried dispersion.

5. The swellable core dosage form according to any one of claims 1-4 for treating an autoimmune disease or auto-inflammatory disease.

6. The swellable core dosage form according to any one of claims 1-4 for treating an inflammatory bowel disease.

7. The swellable core dosage form according to claim 6, wherein the inflammatory bowel disease is ulcerative colitis.

8. The swellable core dosage form according to claim 6, wherein the inflammatory bowel disease is Crohn’s disease.

9. The swellable core dosage form according to any one of claims 1-4 for treating psoriasis.

10. The swellable core dosage form according to claim 9, wherein the psoriasis is plaque psoriasis.

11. The swellable core dosage form according to any one of claims 1-10, wherein the swellable core dosage form is a bi-layer tablet.

12. A swellable core dosage form that is a tablet comprising a core, wherein the core comprises a drug layer and a sweller layer, each layer comprising an osmogen, and wherein the drug layer comprises a dispersion of amorphous 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d_3)pyridazine-3-carboxamide (BMS-986165) dispersed in a polymer matrix.

13. The swellable core dosage form according to claim 12, further comprising a crystallization inhibitor.

14. The swellabe core dosage form according to claim 12, wherein the dispersion of amorphous 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d_3)pyridazine-3-carboxamide (BMS-986165) dispersed in a polymer matrix comprises: 15% amorphous BMS-986165 : 85% hydroxypropyl methylcellulose acetate succinate (HPMCAS).

15. The swellable core dosage form according to claim 12, comprising:

in the drug layer:

22–33% BMS-986165-01 spray-dried dispersion, said spray-dried dispersion comprising 15% BMS-986165-01 and 85% hydroxypropyl methylcellulose acetate succinate (HPMCAS);

0–15% HPMCAS;

42–57% PolyOx having a molecular weight 200,000–5,000,000;

5–15% sodium chloride;

0.5–1% silicon dioxide; and

0.5–1% magnesium stearate;

in the sweller layer:

20–30% microcrystalline cellulose;

60–70% PolyOx having a molecular weight 5,000,000;

5–15% sodium chloride; and

0.5–1% magnesium stearate.

16. The swellable core dosage form according to any one of claims 12-15, wherein the core is coated with a semipermeable coating comprising a water-insoluble polymer.

17. The swellable core dosage form according to claim 16, wherein the semipermeable coating comprises: 60–80% cellulose acetate and 20–40% polyethylene glycol; wherein the semipermeable coating is present in an amount that is 4–22% of the core tablet weight.

18. The swellable core dosage form according to claim 12, wherein the drug layer comprises an intragranular portion and an extragranular portion, and wherein the swellable core dosage form comprises:

in the intragranular portion of the drug layer:

25% BMS-986165-01 spray-dried dispersion, said spray-dried dispersion comprising 15% BMS-986165-01 and 85% hydroxypropyl methylcellulose acetate succinate (HPMCAS);

10% HPMCAS;

54% PolyOx having a molecular weight 200,000–5,000,000;

10% sodium chloride; and

0.25% magnesium stearate;

in the extragranular portion of the drug layer:

0.5% silicon dioxide and

0.25 % magnesium stearate;

in the sweller layer:

25.8% microcrystalline cellulose;

65% PolyOx;
8.5% sodium chloride; and
0.5% magnesium stearate.

19. The swellable core dosage form according to claim 18, wherein the core is coated with a semipermeable coating comprising a 70:30 or 80:20 ratio of cellulose acetate to polyethylene glycol.

20. The swellable core dosage form according to claim 12, comprising:

in the drug layer:

22–33% active consisting of BMS-986165-01 spray-dried dispersion, said spray-dried dispersion comprising 15% BMS-986165-01 and 85% hydroxypropyl methylcellulose acetate succinate (HPMCAS);
0–15% sustaining polymer;
42–57% entraining polymer;
5–15% osmogen;
0.5–1% glidant; and
0.5–1% lubricant;

in the sweller layer:

20–30% filler;
60–70% entraining polymer;
5–15% osmogen; and
0.5–1% lubricant.

21. The swellable core dosage form according to claim 20, wherein the core is coated with a semipermeable coating comprising: 60–80% film forming polymer and 20–40% permeability enhancer; wherein the semipermeable coating is present in an amount that is 4–22% of the core tablet weight.

22. The swellable core dosage form according to any one of claims 12-21, for treating an autoimmune disease or auto-inflammatory disease.

23. The swellable core dosage form according to any one of claims 12-21, for treating an inflammatory bowel disease.

24. The swellable core dosage form according to claim 23, wherein the inflammatory bowel disease is ulcerative colitis.

25. The swellable core dosage form according to claim 23, wherein the inflammatory bowel disease is Crohn's disease.

26. The swellable core dosage form according to any one of claims 12-21, for treating psoriasis.

27. The swellable core dosage form according to claim 26, wherein the psoriasis is plaque psoriasis.

28. Use of the swellable core dosage form according to any one of claims 1-4 in the manufacture of a medicament for treating an autoimmune disease or auto-inflammatory disease.

29. Use of the swellable core dosage form according to any one of claims 1-4 in the manufacture of a medicament for treating an inflammatory bowel disease.

30. The use according to claim 29, wherein the inflammatory bowel disease is ulcerative colitis.

31. The use according to claim 29, wherein the inflammatory bowel disease is Crohn's disease.

32. Use of the swellable core dosage form according to any one of claims 1-4 in the manufacture of a medicament for treating psoriasis.

33. The use according to claim 32, wherein the psoriasis is plaque psoriasis.

34. The use according to any one of claims 28-33, wherein the swellable core dosage form is a bi-layer tablet.

35. Use of the swellable core dosage form according to any one of claims 12-21 in the manufacture of a medicament for treating an autoimmune disease or auto-inflammatory disease.

36. Use of the swellable core dosage form according to any one of claims 12-21 in the manufacture of a medicament for treating an inflammatory bowel disease.

37. The use according to claim 36, wherein the inflammatory bowel disease is ulcerative colitis.

38. The use according to claim 36, wherein the inflammatory bowel disease is Crohn's disease.

39. Use of the swellable core dosage form according to any one of claims 12-21 in the manufacture of a medicament for treating psoriasis.

40. The use according to claim 39, wherein the psoriasis is plaque psoriasis.